 Nanobiotix NASDAQ: NBTX and PharmaEngine Inc have agreed to terminate the license and collaboration agreement announced in August 2012. The agreement provided PharmaEngine exclusive rights to further the development of NBTXR3 in the Asia-Pacific region. 